

• Advancement of Open Science—To what extent does the proposal/prototype advance the goals of open science in biomedical/health research, and fulfill the goals of openness in terms of the product and way of working? To what extent would it move the field forward?

• Impact—What level of impact and benefit could the proposal—if successful—deliver to the research enterprise and health research? Does the proposal/prototype address implementation in multiple settings in a cross-national manner?

• Innovation—What level of creativity and technological innovation does the entrant demonstrate?

• Originality—Is the technology or service genuinely novel and targeting an unmet need? Has the applicant evaluated other existing or alternative approaches, or delineated their approach in comparison to existing approaches (if applicable)?

• Technological viability—Is the approach proposed viable? Can the proposed technology deliver?

• Resource feasibility—Does the team have the required skills and resources?

Judges will rate each entry on five-point scale from Not-fundable (1) to Outstanding (5). The NIH and WT will hold separate judging panels, and then will discuss priorities for selection of the respective winners (in Phase I), and the final winner (in Phase II).

For Phase II, public voting will select the top 3 prototypes of the 6 Phase I finalist, followed by a review of the prototypes for feasibility and technical merit by external advisors with expertise in Open Science. Prototypes will then be scored by Judges using the initial Phase I criteria.

### Intellectual Property

By submitting an Entry, each Solver warrants that he or she is the sole author and owner of any copyrightable works that the Entry comprises (or has obtained sufficient rights in any copyrightable works owned by third parties to satisfy its obligations set forth herein), that the works are wholly original with the Solver (or is an improved version of an existing work that the Solver has sufficient rights to use and improve), and that the Entry does not infringe any copyright or any other rights of any third party of which Solver is aware.

To receive an award, Solvers will not be required to transfer their intellectual property rights to the NIH or the Challenge Partners. Each Solver retains title to their Entry, including object and source code, and expressly reserves all intellectual property rights (*e.g.*, copyrights and rights to inventions and

patents that cover them) in their Entry, unless the Solver chooses an open license for the Entry. By participating in the Challenge each Solver grants to the U.S. government a nonexclusive, non-transferrable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States any invention throughout the world owned or controlled by the Solver that covers the Entry, and grants to the U.S. government and others acting on behalf of the U.S. government, a royalty-free, irrevocable, non-exclusive worldwide license to use, reproduce, and display publicly all parts of the Entry for the purposes of the Challenge. This license includes without limitation posting or linking to the Entry on the official Challenge Web site and, except for object code or source code, making the Entry available for research use by the public. Notwithstanding the above and consistent with the principal objective of the challenge to make results widely available to the public, the NIH encourages the Solver to distribute any computer code (object code and preferably also source code) that is part of the Entry to the public under a liberal open source license that permits the public to benefit from and improve upon the Entry (see the licenses available at <http://opensource.org/licenses/>). The Solver should include in its submission a description of how and under what license terms it intends to make any computer code that is part of the Entry available to the public.

Solvers are free to discuss their Entry and the ideas or technologies that it contains with other parties, encouraged to share ideas/technologies publicly, and are free to contract with any third parties, as long as they do not sign any agreement or undertake any obligation that conflicts with the Challenge rules set forth herein. For the purpose of clarity, Solvers acknowledge that the intent of the Challenge is to encourage people to collaborate and share ideas and innovations.

### Liability and Indemnification

By participating in this Challenge, each Solver agrees to assume any and all risks and waive claims against the U.S. federal government and its related entities (as defined in the COMPETES Act), including Capital Consulting Corporation, the Challenge Expert Science Advisors and Judges, except in the case of willful misconduct, for any injury, death, damage, or loss of property, revenue, or profits, whether direct, indirect, or consequential, arising from participation in this Challenge, whether the injury, death, damage, or loss arises through negligence or

otherwise. By participating in this Challenge, each Solver agrees to indemnify the federal government and the Capital Consulting Corporation against third party claims for damages arising from or related to Challenge activities.

### Insurance

Based on the subject matter of the Challenge, the type of work that it will possibly require, as well as an analysis of the likelihood of any claims for death, bodily injury, or property damage, or loss potentially resulting from competition participation, Solvers are not required to obtain liability insurance or demonstrate financial responsibility in order to participate in this Challenge.

Dated: September 28, 2015.

**Lawrence A. Tabak,**

*Deputy Director, National Institutes of Health.*

[FR Doc. 2015-26392 Filed 10-19-15; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel.

*Date:* November 3, 2015.

*Time:* 1:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Democracy Blvd., Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Yin Liu, Ph.D., MD, Scientific Review Officer Scientific Review Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health Bethesda, MD 20892, 301-496-0505, [liuy@mail.nih.gov](mailto:liuy@mail.nih.gov).

*Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel.

*Date:* November 4, 2015.

*Time:* 9:00 a.m. to 1:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Democracy Blvd., Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* Yin Liu, Ph.D., MD, Scientific Review Officer Scientific Review Branch National Institute of Arthritis, and Musculoskeletal and Skin Diseases National Institute of Health Bethesda, MD 20892, 301-496-0505, [liyuy@mail.nih.gov](mailto:liyuy@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: October 14, 2015.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-26563 Filed 10-19-15; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Mental Health; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Mental Health Special Emphasis Panel, October 26, 2015, 01:30 p.m. to October 26, 2015, 05:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 which was published in the **Federal Register** on September 28, 2015, 80 FR 58272.

This meeting is being amended to add a panel name. The panel name is "Fellowships and Dissertation Grants." The meeting is closed to the public.

Dated: October 14, 2015.

**Carolyn A. Baum,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-26560 Filed 10-19-15; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Mental Health; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Institute of Mental Health Special Emphasis Panel, October 14, 2015, 3:00 p.m. to October 14, 2015, 5:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 which was published in the

**Federal Register** on September 18, 2015, 80 FR 56474.

This meeting is being amended to add a panel name. The panel name is "Career Award." The meeting is closed to the public.

Dated: October 14, 2015.

**Carolyn A. Baum,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-26561 Filed 10-19-15; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Microbiology, Infectious Diseases and AIDS Initial Review Group; Acquired Immunodeficiency Syndrome Research Review Committee.

*Date:* November 9-10, 2015.

*Time:* November 9, 2015, 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Room 3F100, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call).

*Time:* November 10, 2015, 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Room 8F100, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call).

*Contact Person:* Brenda L. Fredericksen, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3G22A, National Institutes of Health/NIAD, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5052, [brenda.fredericksen@nih.gov](mailto:brenda.fredericksen@nih.gov).

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Limited Competition: International Epidemiology Databases to Evaluate AIDS (IeDEA) (U01).

*Date:* November 16-17, 2015.

*Time:* 12:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Room 4F100, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call).

*Contact Person:* Kelly Y. Poe, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3F40B, National Institutes of Health, NIAD, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5036, [poeky@mail.nih.gov](mailto:poeky@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: October 14, 2015.

**Michelle Trout,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-26555 Filed 10-19-15; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Heart, Lung, and Blood Initial Review Group; NHLBI Mentored Transition to Independence Review Committee.

*Date:* November 5-6, 2015.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The William F. Bolger Center, 9600 Newbridge Drive, Potomac, MD 20854.

*Contact Person:* Giuseppe Pintucci, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7192, Bethesda, MD 20892, 301-435-0287, [Pintuccig@nhlbi.nih.gov](mailto:Pintuccig@nhlbi.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases